Jeff Haince - BioMark Diagnostics GM Officer

BMKDF Stock  USD 0.15  0.01  6.25%   

Insider

Jeff Haince is GM Officer of BioMark Diagnostics
Phone604 370 0779
Webhttps://www.biomarkdiagnostics.com

BioMark Diagnostics Management Efficiency

The company has return on total asset (ROA) of (1.4493) % which means that it has lost $1.4493 on every $100 spent on assets. This is way below average. BioMark Diagnostics' management efficiency ratios could be used to measure how well BioMark Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.
BioMark Diagnostics has accumulated 96.3 K in total debt. BioMark Diagnostics has a current ratio of 0.34, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist BioMark Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, BioMark Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioMark Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioMark to invest in growth at high rates of return. When we think about BioMark Diagnostics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Bob HalbertStar Equity Holdings
N/A
Richard ColemanStar Equity Holdings
68
Claire SearsNeuronetics
N/A
Stephen MSNeuronetics
60
Dr IIIBiodesix
53
BBus CAIntelligent Bio Solutions
60
Ruth VilligerWilsonRadNet Inc
60
Ahmed SabetPrecipio
38
Paul BeresfordBiodesix
N/A
Xavier MSbioAffinity Technologies Warran
54
Bobbi CoffinBiodesix
N/A
Miri ChikoRadomskiPrecipio
N/A
Thomas TheuringerQiagen NV
N/A
Billy WhiteProPhase Labs
63
Heinrich RderBiodesix
N/A
Ranjan JayanathanRadNet Inc
68
Martin ShirleyStar Equity Holdings
62
Kara ThorntonNeuronetics
N/A
Matthew GagePrecipio
57
Gary PestanoBiodesix
57
Andrew MacanNeuronetics
51
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc. Biomark Diagnostics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. BioMark Diagnostics [BMKDF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

BioMark Diagnostics Leadership Team

Elected by the shareholders, the BioMark Diagnostics' board of directors comprises two types of representatives: BioMark Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioMark. The board's role is to monitor BioMark Diagnostics' management team and ensure that shareholders' interests are well served. BioMark Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioMark Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Daniel Sitar, Principal Advisor
Guoyu MBA, Chief Officer
Jeff Haince, GM Officer
Neal Kaplan, CFO of US

BioMark Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BioMark Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in BioMark Pink Sheet

BioMark Diagnostics financial ratios help investors to determine whether BioMark Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMark with respect to the benefits of owning BioMark Diagnostics security.